Topix Pharmaceuticals, Inc. has acquired Derma E, a California-based eco-ethical skin care brand.

The partnership with Topix will provide Derma E with additional resources to support its category-leading growth while expanding the Topix family of brands, and Topix’s commitment to advancing healthy, beautiful skin, into the increasingly important and high- growth naturals category.

Topix is backed by New Mountain Capital, a growth-oriented investment firm that currently manages more than $20 billion in assets. New Mountain Capital invested in Topix in July 2016 to provide equity capital for Topix to execute a growth strategy, including both organic and acquisition-led growth.

“We are thrilled to welcome Derma E into the Topix family,” said Andre Moura, Managing Director at New Mountain Capital and Chairman of the Topix Board of Directors. “Topix is a leader in the dermatologist market with differentiated innovation and FDA- certified manufacturing capabilities. We look forward to supporting Derma E and its customers with these resources and believe the partnership will create multiple new avenues of long-term growth for both Derma E and the broader Topix business.”

Following the acquisition, Derma E will continue to operate in Simi Valley, CA and will continue its commitment to providing consumers with the leading portfolio of clinically-supported, natural skincare products.

“Derma E is an important first step in expanding Topix into adjacent, high-growth categories with a highly complementary brand that resonates deeply with consumers and  shares Topix’s commitment to innovation,” said Burt Shaffer, founder and chief executive Officer of Topix.

“Topix is an ideal partner to help Derma E not only accelerate its growth plans but also ensure that the integrity of the brand and its mission remain,” commented David Stearn, co-founder and CEO of Derma e. “Topix is highly regarded amongst dermatologists as a leader in innovative and clinically-validated skincare products and we believe several new opportunities can be opened for Derma e as a result of this transaction.”

Topix is an independent leader in skincare with a differentiated portfolio of clinically-proven products and brands sold across high-growth channels. Topix was founded in 1981 and built its reputation in the physician market where it is the largest provider of premium, micro- branded and branded skincare products, partnering with over 3,000 physicians in the U.S. Topix’s portfolio of products are clinically-validated and manufactured in the Company’s state-of-the-art, FDA-registered facility in New York.